BACE1 Antibodies

Structure of BACE1

BACE1 is a relatively large type I transmembrane protein, and the molecular weight of its precursor protein is approximately 75 kDa. The molecular weight of mature BACE1 protein is approximately 65 kDa. This difference mainly results from the excision of the N-terminal signal peptide and the pre-domain during processing.

This protein is generated by post-translational modification of a precursor composed of 501 amino acids. Its structure contains a large extracellular catalytic domain, which is mainly composed of multiple β -sheets, forming a classic "aspartic acid protease folding" structure, with two key catalytic aspartic acid residues at the center. A transmembrane domain and a short C-terminal cytoplasmic tail region jointly anchor its localization on the cell membrane. Its active site is located in a hydrophobic port pocket of the extracellular domain and is responsible for specifically recognizing and cleapping substrates such as amyloid precursor proteins.

Fig. 1 BACE1 crystal structure made using structure 3TPR on RSCB Protein DataBank.¹

Key structural properties of BACE1:

• Typical aspartic acid protease folding configuration
• Conservative catalytic diad
• Unique substrate binding channels
• Transmembrane anchoring domain

Functions of BACE1

The main function of BACE1 is to act as a β -secretase and participate in the pathological process of Alzheimer's disease. However, it also involves a variety of physiological and pathological processes.

Unlike myoglobin, which has a single oxygen-binding function, BACE1 exhibits complex substrate selectivity. Its catalytic efficiency is precisely regulated by multiple factors such as substrate sequence, cellular localization, and microenvironmental pH, demonstrating the diversity of its functions.

Applications of BACE1 and BACE1 Antibody in Literature

• Taylor, Hannah A., et al. "BACE1: More than just a β‐secretase." Obesity Reviews 23.7 (2022): e13430. https://doi.org/10.1111/obr.13430

Traditionally, BACE1 has been regarded as an enzyme related to Alzheimer's disease. New research has found that it is abnormally expressed in peripheral cells such as the pancreas and fat, and is associated with the development of metabolic diseases such as diabetes and obesity. Its knockout mouse model showed weight loss and increased energy expenditure, suggesting that BACE1 inhibitors may provide new therapies for obesity and related metabolic diseases.

• Cervellati, Carlo, Giuseppe Valacchi, and Giovanni Zuliani. "BACE1: from biomarker to Alzheimer's disease therapeutical target." Aging (Albany NY) 13.9 (2021): 12299. https://doi.org/10.18632/aging.203064

The article indicates that BACE1 is the key enzyme for generating the crucial pathogenic substance Aβ in Alzheimer's disease. Its activity is elevated in both the brain and peripheral blood of patients, and it has the potential to become a low-cost screening marker. Although BACE1 inhibitors can effectively reduce Aβ, clinical trials have failed to improve patients' cognition, and their therapeutic value is facing challenges.

• Bazzari, Firas H., and Amjad H. Bazzari. "Bace1 inhibitors for Alzheimer's disease: the past, present and any future?." Molecules 27.24 (2022): 8823. https://doi.org/10.3390/molecules27248823

The article indicates that BACE1 inhibitors aim to treat Alzheimer's disease by blocking amyloid protein production. Although the early research prospects were optimistic, almost all candidate drugs failed in later clinical trials due to efficacy or safety issues, and their future development paths still face severe challenges.

• Cervellati, Carlo, Giuseppe Valacchi, and Giovanni Zuliani. "Early elevation of BACE1 in dementia." Aging (Albany NY) 13.22 (2021): 24480. https://doi.org/10.18632/aging.203727

Research has found that BACE1 activity increases in the preclinical stage of Alzheimer's disease and may drive early asymptomatic neuropathy. This indicator may serve as an early screening marker, but as its effect weakens in the late stage of the disease, treatment targeting it needs to be initiated at an earlier stage.

• Koelsch, Gerald. "BACE1 function and inhibition: implications of intervention in the amyloid pathway of Alzheimer's disease pathology." Molecules 22.10 (2017): 1723. https://doi.org/10.3390/molecules22101723

Research has found that BACE1 is A key enzyme in the production of Aβ, and its inhibitors can block the early pathology of Alzheimer's disease. However, inhibiting its activity may also affect the normal physiological functions of the brain and peripheral nerves. The therapeutic effect and potential risks need to be carefully weighed in clinical trials.

Creative Biolabs: BACE1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality BACE1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom BACE1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our BACE1 antibodies, custom preparations, or technical support, contact us at email.